BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Londoño MC, Lens S, Mariño Z, Bonacci M, Ariza X, Broquetas T, Pla A, Bartres C, Adriani MV, Rodríguez-Tajes S, Costa J, Carrión JA, Pérez-Del-Pulgar S, Forns X. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharmacol Ther 2017;45:1156-61. [PMID: 28206681 DOI: 10.1111/apt.13985] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Londoño M, Carrión JA, Forns X. Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors' reply. Aliment Pharmacol Ther 2017;45:1559-60. [DOI: 10.1111/apt.14104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
2 Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12:56-67. [PMID: 28702738 DOI: 10.1007/s12072-017-9807-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
3 Naderi N, Masoudi G, Behnava B, Alavian SM, Sari S, Anvar A, Azizi Saraji A, Namvar A, Bolhassani A. Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.83337] [Reference Citation Analysis]
4 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 El Kassas M, Shimakawa Y, Ali-Eldin Z, Funk AL, Wifi MN, Zaky S, El-Raey F, Esmat G, Fontanet A. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int 2018;38:2159-69. [PMID: 29738637 DOI: 10.1111/liv.13874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Huang R, Yan X, Xia J, Wang J, Wu C. Letter: hepatitis B virus reactivation in patients with chronic hepatitis C during direct-acting anti-viral therapy. Aliment Pharmacol Ther 2017;45:1558. [PMID: 28503862 DOI: 10.1111/apt.14080] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Shiffman ML, Gunn NT. Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Curr Hepatology Rep 2017;16:169-77. [DOI: 10.1007/s11901-017-0352-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Papadopoulos N, Papavdi M, Pavlidou A, Konstantinou D, Kranidioti H, Kontos G, Koskinas J, Papatheodoridis GV, Manolakopoulos S, Deutsch M. Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues. Ann Gastroenterol 2018;31:365-70. [PMID: 29720863 DOI: 10.20524/aog.2018.0255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Pisaturo M, Macera M, Alessio L, Calò F, Coppola N. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses 2019;11:E850. [PMID: 31540223 DOI: 10.3390/v11090850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Sastre L, Ruiz P, Costa J, Forns X. Severe hepatitis B reactivation during direct-acting antiviral treatment in "the absence" of hepatitis B surface antigen. Int J Infect Dis 2019;79:47-9. [PMID: 30496851 DOI: 10.1016/j.ijid.2018.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Preda CM, Popescu CP, Baicus C, Constantinescu I, Oproiu A, Voiosu T, Diculescu M, Negreanu L, Gheorghe L, Sporea I, Trifan A, Ceausu E, Proca D, Manuc M. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin. J Viral Hepat 2018;25:834-41. [PMID: 29397016 DOI: 10.1111/jvh.12872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. Journal of Hepatology 2019;70:874-84. [DOI: 10.1016/j.jhep.2019.01.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
15 Shih YF, Liu CJ. Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses 2020;12:E741. [PMID: 32664198 DOI: 10.3390/v12070741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67:411-431. [PMID: 28683174 DOI: 10.3322/caac.21403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
17 Huang R, Wang J, Hao Y, Yan X, Wu C. Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy. Aliment Pharmacol Ther 2017;46:702-3. [PMID: 28880444 DOI: 10.1111/apt.14227] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Mücke MM, Backus LI, Mücke VT, Coppola N, Preda CM, Yeh M, Tang LSY, Belperio PS, Wilson EM, Yu M, Zeuzem S, Herrmann E, Vermehren J. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2018;3:172-80. [DOI: 10.1016/s2468-1253(18)30002-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 30] [Article Influence: 20.3] [Reference Citation Analysis]
19 Morales-Arraez D, Diaz-Flores F, Alonso A, de Vera A, Jimenez A, Garcia Dopico JA, Quintero E, Hernández-Guerra M. Patients with suboptimal hepatitis B virus diagnostic characterization are at risk of liver fibrosis progression. Eur J Gastroenterol Hepatol 2020;32:426-32. [PMID: 31490418 DOI: 10.1097/MEG.0000000000001527] [Reference Citation Analysis]
20 Jaroszewicz J, Pawłowska M, Simon K, Zarębska-Michaluk D, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Paluch K, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Flisiak R. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther 2020;18:1045-54. [PMID: 32538232 DOI: 10.1080/14787210.2020.1782189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Butt AA, Yan P, Shaikh OS, Abou-Samra AB. Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:412-20. [PMID: 29181838 DOI: 10.1111/apt.14426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
22 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol 2018;33:710-7. [PMID: 28762541 DOI: 10.1111/jgh.13912] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
23 Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018;154:989-97. [PMID: 29174546 DOI: 10.1053/j.gastro.2017.11.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
24 Blackard JT, Sherman KE. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV). Rev Med Virol 2018;28:e1984. [PMID: 29761585 DOI: 10.1002/rmv.1984] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
25 Wang CC, Kao JH. Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation. Aliment Pharmacol Ther 2017;46:208. [PMID: 28621067 DOI: 10.1111/apt.14116] [Reference Citation Analysis]
26 Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol 2018; 24(28): 3181-3191 [PMID: 30065564 DOI: 10.3748/wjg.v24.i28.3181] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
27 Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M, Capeau J, Carrieri P, Larrey D, Larsen C, Marcellin P, Pawlostky JM, Nahon P, Zoulim F, Cacoub P, de Ledinghen V, Mathurin P, Negro F, Pageaux GP, Yazdanpanah Y, Wittkop L, Zarski JP, Carrat F; French Anrs Co22 Hepather Cohort. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther 2017;46:1054-60. [PMID: 28994127 DOI: 10.1111/apt.14352] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
28 Hsu CS, Wang PC, Li CH, Lin HH. Letter: HBV/HCV coinfection in the era of direct-acting antivirals. Aliment Pharmacol Ther 2017;46:211. [PMID: 28621068 DOI: 10.1111/apt.14127] [Reference Citation Analysis]
29 Güçlü E, Alan S, Karabay O. Hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic Hepatitis C. Turk J Gastroenterol 2020;31:344-5. [PMID: 32412906 DOI: 10.5152/tjg.2020.18082] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, Scuteri A, Vitale G, Di Donato R, Cursaro C. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66-70. [PMID: 28654775 DOI: 10.1016/j.jcv.2017.05.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
31 Chen C. Editorial: hepatitis B reactivation in patients with chronic hepatitis C treated with direct-acting antivirals - incidence, severity of hepatitis and lessons to learn. Aliment Pharmacol Ther 2017;45:1373-4. [DOI: 10.1111/apt.14051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. Ann Pharmacother 2019;53:294-310. [PMID: 30203666 DOI: 10.1177/1060028018800501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Abdelbary MS, Samir R, El-nahaas SM, Hosny Shahin RM, El-sayed M, Gaber Y, Tantawi O, Zayed NA, Yosry A. Hepatitis B reactivation following eradication of HCV with direct-acting antiviral drugs (DAAs) in a cohort of patients from different institutions in Egypt. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.020] [Reference Citation Analysis]
34 Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment Pharmacol Ther 2017;46:432-9. [PMID: 28627791 DOI: 10.1111/apt.14177] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
35 Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J. Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. Open Forum Infect Dis 2019;6:ofy340. [PMID: 30648130 DOI: 10.1093/ofid/ofy340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
36 Antón MD, Polanco A, Ferrando I, Latorre P, Pascual A, Moreno Osset E. Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals. Gastroenterol Hepatol 2018;41:317-9. [PMID: 28728831 DOI: 10.1016/j.gastrohep.2017.06.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]